Table 6.
Federated machine learning implementations in cancer prediction.
| Ref | Disease | Data Used | Performance |
|---|---|---|---|
| [130] | Brain tumor | Brain MRI Segmentation Kaggle dataset [131] | FL results outperform the baseline but classical ML models competed with their results |
| [132] | Brain tumor | BraTS dataset [133] | Dice = 0.86 for both FL and ML scenarios |
| [134] | Brain tumor | BraTS dataset [133] | FL performance is similar to ML models |
| [135] | Brain tumor | Private data | Dice=0.86 for both FL and ML scenarios |
| [136] | Skin cancer | ISIC 2018 dataset [137] | Accuracy = 91% for both FL and ML scenarios |
| [138] | Skin cancer | ISIC 2019 Dermoscopy dataset [137] | Accuracy: 89% which outperformed previous implementations |
| [139] | Breast cancer | Private data from 7 different institutions | FL perform 6.3% on average better than classical ML |
| [140] | Breast cancer | Obtained from Netherlands Cancer Registry (NCR) | Not available |
| [141] | Prostate cancer | Private data | FL model exhibited superior performance and generalizability to the ML models |
| [142] | Lung cancer | Private data from 8 institutes across 5 countries | Not available |
| [143] | Pancreatic cancer | Data from hospitals in Japan and Taiwan | FL models have higher generalizability than ML models |
| [144] | Thyroid cancer | Private data from 6 institutions | DL models outperformed FL models |
| [145] | Anal cancer | Private data from 3 institutions | Not available |